Prostate Cancer Management with Multimodality Imaging

多模态成像治疗前列腺癌

• 批准号: 7625134
• 负责人: Youngho Seo
• 金额: $ 13.75万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-07-12 至 2011-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7625134
• 关键词: Aptitude; Area; Arts; Beds; Cancer Detection; Capromab Pendetide; Carbon; Choline; Clinical; Clinical Management; Collaborations; Detection; Diagnostic Neoplasm Staging; Disease; Distant; Evaluation; Feasibility Studies; Fluorine; Gland; Gleason Grade for Prostate Cancer; Goals; Healthcare; Image; Imaging Techniques; Indium-111; Knowledge; Label; Lesion; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Malignant Neoplasms; Malignant neoplasm of prostate; Measurement; Medical; Mentors; Metabolic; Methods; Metric; Modality; Monitor; Monoclonal Antibodies; Neoplasm Metastasis; Operative Surgical Procedures; Outcome; Pathologic; Pathology; Patients; Physics; Prostate; Radiation; Radiation therapy; Radiolabeled; Radionuclide Imaging; Research; Research Personnel; Resolution; Science; Solutions; Staging; System; Techniques; Training; Ultrasonography; X-Ray Computed Tomography; anticancer research; base; cancer imaging; experience; high risk; hormone therapy; imaging modality; improved; lymph nodes; multimodality; programs; radiotracer; single photon emission computed tomography; skills; treatment planning; uptake

DESCRIPTION (provided by applicant): Substantial advances in prostate cancer management have been made with noninvasive imaging techniques including radionuclide imaging and magnetic resonance spectroscopy imaging (MRSI) in addition to conventional structural imaging techniques, computed tomography (CT), magnetic resonance imaging (MRI), and transrectal ultrasonography (TRUS). However, no single imaging technique has demonstrated the breadth of functionality needed to assess prostate cancer. In addition, a coherent multimodality approach using these already available imaging techniques has not been established for the clinical management of this disease. We therefore propose to develop an approach to present a comprehensive set of functional, metabolic, biomolecular, and structural imaging modalities for the same patient to improve management of patients with prostate cancer. The goal of this project is to develop an approach that combines information from multiple imaging modalities and to develop a method to improve the current prostate cancer management in both pretherapy and posttherapy cases. In this study, we will focus on the dual-modality SPECT/CT imaging using an indium-111 radiolabeled monoclonal antibody and MRI/MRSI techniques during initial periods of the project. Goal 1: A method will be developed to quantify 111ln-labeled capromab pendetide (ProstaScint(R), Cytogen Corporation, Princeton, NJ) activity in phantoms and patients with a commercial SPECT/CT system (Discovery VH Hawkeye, GE Healthcare, Waukesha, Wl). The methods of quantifying 111ln-ProstaScint(R) uptake then will be extended to an approach that combines SPECT/CT and MRI/MRSI for assessment of prostate cancer. Goal 2: We will develop methods that correlate SPECT/CT and MRI/MRSI images to evaluate patients at a high risk of having metastasized cancer with a goal of assisting radiation treatment planning. The quantitative measurements and correlations from 111ln-ProstaScint( R)SPECT/CT and MRI/MRSI studies developed from Goal 1 and 2 then can guide radiation therapy planning which will be pursued under Goal 3. Goal 3: A method to implement the correlative image presentation in radiation treatment planning will be developed. We believe that outcomes from the successful completion of the proposed research program will not only enhance the clinical prostate cancer management but also provide valuable aptitude skills and knowledge for the candidate to become an independent biomedical researcher with strong background in quantitative sciences.

描述（由申请人提供）：除了传统的结构成像技术，计算机术（CT），磁共振成像（MRI）和transectal ultrectal improsonography（trus（Trus）外，除了放射性成像成像和磁共振光谱成像（MRSI）外，还通过包括放射性核素成像和磁共振光谱成像（MRSI）（MRSI）进行了前列腺癌管理的实质进步。但是，没有单个成像技术表明评估前列腺癌所需的功能广度。此外，尚未建立使用这些已经可用的成像技术的连贯的多模式方法来进行该疾病的临床管理。因此，我们建议为同一患者提供一组全面的功能，代谢，分子和结构成像方式，以改善前列腺癌患者的管理。该项目的目的是开发一种方法，该方法结合了来自多种成像方式的信息，并开发一种方法来改善预亲治疗和治疗后病例中当前的前列腺癌管理。在这项研究中，我们将使用Indium-11111放射性标记的单克隆抗体和MRI/MRSI技术在项目的初始期间专注于双模式SPECT/CT成像。 目标1：将开发一种方法来量化111LN标记的capromab pendetide（Prostascint（R），Cytogen Corporation，Cytogen Corporation，Princeton，NJ）在幻影和具有商业Spect/CT系统的患者中（Discovery VH Hawkeye，Ge Hawkeye，GE Healthare，Waukesha，Waukesha，WL）。然后，量化111LN-局明（R）摄取的方法将扩展到结合SPECT/CT和MRI/MRSI以评估前列腺癌的方法。 目标2：我们将开发将SPECT/CT和MRI/MRSI图像相关联的方法，以评估患有转移癌症的高风险的患者，目的是协助放射治疗计划。从目标1和2开发的111 ln-Prostastint/ct/MRI/MRSI研究的定量测量和相关性可以指导放射治疗计划，该计划将在目标3下进行。 目标3：将开发一种在辐射处理计划中实施相关图像呈现的方法。 我们认为，成功完成拟议的研究计划后的结果不仅会增强临床前列腺癌管理，而且还提供了有价值的才能和知识，使候选人成为具有较强定量科学背景的独立生物医学研究人员。